Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer

Inclusion Criteria: * Adult patients with histologically-confirmed recurrent non-small cell lung cancer have had at least two prior systemic treatment regimens * Must have measurable disease according to RECIST * Eastern Cooperative Oncology Group performance status 0-1 * Adequate bone marrow, hepatic and renal function * Ability to swallow capsules * At least 3 weeks from prior systemic treatments including investigational anti-cancer therapy, at least 7 days from prior radiation therapy and have recovered from prior toxicities * At least 3 weeks from major surgery Exclusion Criteria: * Non-small cell cancer histology contains a component of small cell lung cancer * Previously untreated CNS metastasis or progressive CNS metastasis * Prior treatment with a CDK inhibitor * Currently receiving radiotherapy, biological therapy, or any other investigational therapy * Uncontrolled intercurrent illness * Having other cancers that have been treated with chemotherapy or biological therapy in the past 5 years with the exception of adequately treated in situ cervical cancer or basal cell skin cancer * Pregnant or lactating women * Known to be HIV-positive * Active hepatitis B and/or hepatitis C infection